FDA Okays First-Ever New Drug for Rare Bone Disorder

The retinoid palovarotene reduces abnormal bone growth in children and adults with fibrodysplasia ossificans progressive.
FDA Approvals

source https://www.medscape.com/viewarticle/995579?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension